Your browser doesn't support javascript.
loading
High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells.
Kim, Hui Kwon; Lee, Sungtae; Kim, Younggwang; Park, Jinman; Min, Seonwoo; Choi, Jae Woo; Huang, Tony P; Yoon, Sungroh; Liu, David R; Kim, Hyongbum Henry.
Affiliation
  • Kim HK; Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Lee S; Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Kim Y; Center for Nanomedicine, Institute for Basic Science (IBS), Seoul, Republic of Korea.
  • Park J; Yonsei-IBS Institute, Yonsei University, Seoul, Republic of Korea.
  • Min S; Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Choi JW; Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Huang TP; Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Yoon S; Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Liu DR; Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Kim HH; Electrical and Computer Engineering, Seoul National University, Seoul, Republic of Korea.
Nat Biomed Eng ; 4(1): 111-124, 2020 01.
Article in En | MEDLINE | ID: mdl-31937939
ABSTRACT
The applications of clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing can be limited by a lack of compatible protospacer adjacent motifs (PAMs), insufficient on-target activity and off-target effects. Here, we report an extensive comparison of the PAM-sequence compatibilities and the on-target and off-target activities of Cas9 from Streptococcus pyogenes (SpCas9) and the SpCas9 variants xCas9 and SpCas9-NG (which are known to have broader PAM compatibility than SpCas9) at 26,478 lentivirally integrated target sequences and 78 endogenous target sites in human cells. We found that xCas9 has the lowest tolerance for mismatched target sequences and that SpCas9-NG has the broadest PAM compatibility. We also show, on the basis of newly identified non-NGG PAM sequences, that SpCas9-NG and SpCas9 can edit six previously unedited endogenous sites associated with genetic diseases. Moreover, we provide deep-learning models that predict the activities of xCas9 and SpCas9-NG at the target sequences. The resulting deeper understanding of the activities of xCas9, SpCas9-NG and SpCas9 in human cells should facilitate their use.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CRISPR-Cas Systems / Gene Editing / CRISPR-Associated Protein 9 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Biomed Eng Year: 2020 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CRISPR-Cas Systems / Gene Editing / CRISPR-Associated Protein 9 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Biomed Eng Year: 2020 Type: Article